NOVO-OXCARBAZEPINE 300 MG
OXCARBAZEPINE : 300 MG · DIN 02312034 · NOVOPHARM LIMITED
Health Canada status: CANCELLED PRE MARKET
What is NOVO-OXCARBAZEPINE?
NOVO-OXCARBAZEPINE 300 MG contains OXCARBAZEPINE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02312034, held by NOVOPHARM LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 24-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02312034 |
|---|---|
| Brand name | NOVO-OXCARBAZEPINE |
| Generic / active ingredient | OXCARBAZEPINE : 300 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AF02 OXCARBAZEPINE |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 24-Jul-2018 |
What can be used instead?
Other Canadian products sharing ATC code N03AF02 OXCARBAZEPINE. 9 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXCARBAZEPINE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02284294 |
| APO-OXCARBAZEPINE | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02284308 |
| APO-OXCARBAZEPINE | 600 MG | TABLET | APOTEX INC | MARKETED | DIN 02284316 |
| JAMP OXCARBAZEPINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02560593 |
| JAMP OXCARBAZEPINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02560607 |
| JAMP OXCARBAZEPINE | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02560615 |
| TRILEPTAL 300 MG | 300 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02242068 |
| TRILEPTAL 600 MG | 600 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02242069 |
| TRILEPTAL ORAL SUSPENSION | 60 MG | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02244673 |
| JAMP-OXCARBAZEPINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | CANCELLED POST MARKET | DIN 02440717 |
Who else supplies OXCARBAZEPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXCARBAZEPINE appears in 50 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.